Fluoguide AS (FLUO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fluoguide AS (FLUO) has a cash flow conversion efficiency ratio of 4.485x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.97 Million ≈ $-1.18 Million USD) by net assets (Skr-2.44 Million ≈ $-263.12K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Fluoguide AS (FLUO) defensive interval to measure how many days the company can operate on defensive assets alone.
Fluoguide AS - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Fluoguide AS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fluoguide AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fluoguide AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seouleaguer Co. Ltd
KQ:043710
|
0.033x |
|
Heron Therapeuti
NASDAQ:HRTX
|
-0.169x |
|
Advero Properties SOCIMI S.A.
MC:YADV
|
0.008x |
|
Thai Wah Public Company Limited
BK:TWPC
|
-0.019x |
|
Coffee Day Enterprises Limited
NSE:COFFEEDAY
|
0.025x |
|
Daesung Holdin
KO:016710
|
-0.019x |
|
Guizhou Zhongyida Co Ltd
SHG:900906
|
0.253x |
|
Nanoform Finland Plc
HE:NANOFH
|
-0.076x |
Annual Cash Flow Conversion Efficiency for Fluoguide AS (2018–2024)
The table below shows the annual cash flow conversion efficiency of Fluoguide AS from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Fluoguide AS market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr23.07 Million ≈ $2.48 Million |
Skr-29.15 Million ≈ $-3.14 Million |
-1.264x | +49.46% |
| 2023-12-31 | Skr12.72 Million ≈ $1.37 Million |
Skr-31.81 Million ≈ $-3.42 Million |
-2.501x | -112.36% |
| 2022-12-31 | Skr31.97 Million ≈ $3.44 Million |
Skr-37.65 Million ≈ $-4.05 Million |
-1.178x | -202.57% |
| 2021-12-31 | Skr38.70 Million ≈ $4.16 Million |
Skr-15.06 Million ≈ $-1.62 Million |
-0.389x | +80.60% |
| 2020-12-31 | Skr4.41 Million ≈ $474.69K |
Skr-8.85 Million ≈ $-952.08K |
-2.006x | +13.68% |
| 2019-12-31 | Skr4.54 Million ≈ $488.79K |
Skr-10.55 Million ≈ $-1.14 Million |
-2.323x | -1390.74% |
| 2018-12-31 | Skr7.00K ≈ $753.31 |
Skr-1.09K ≈ $-117.41 |
-0.156x | -- |
About Fluoguide AS
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical T… Read more